Document:

EX-4.1

 Exhibit 4.1 

COMPOSITE CERTIFICATE OF INCORPORATION OF 

CYTORI THERAPEUTICS, INC. 

ARTICLE I 
 The name of the corporation is Cytori
Therapeutics, Inc. (the “Corporation”). 
 ARTICLE II 

The address of the registered office of the Corporation in the State of Delaware is: 

CorpAmerica, Inc. 

2711 Centerville Road, Suite 400 

Wilmington, DE 19808 

County of New Castle 
 The name
of the Corporation’s registered agent at said address is CorpAmerica, Inc. 
 ARTICLE III 

The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the
State of Delaware (the “Delaware General Corporation Law”). 
 ARTICLE IV 

A. This Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The
total number of shares which the Corporation is authorized to issue is One Hundred Fifty Million (150,000,000) shares, One Hundred Forty-Five Million (145,000,000) shares of which shall be Common Stock (the “Common Stock”) and
Five Million (5,000,000) shares of which shall be Preferred Stock (the “Preferred Stock”). The Common Stock and the Preferred Stock shall each have a par value of $0.001 per share. 

B. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares of Common Stock then outstanding) by the
affirmative vote of the holders of a majority of the stock of the Corporation. 
 C. The Preferred Stock may be issued from time to time in one or more
series. The Board of Directors is hereby authorized, within the limitations and restrictions stated in this Amended and Restated Certificate of Incorporation, to fix or alter the dividend rights, dividend rate, conversion rights, voting rights,
rights and terms of redemption (including sinking fund provisions), the redemption price or prices, the liquidation preferences of any wholly unissued series of Preferred Stock, and the number of shares constituting any such series and the
designation thereof, or any of them; and to increase or decrease the number of shares of any series subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of
any series shall be so decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series. 

ARTICLE V 
 The Board of Directors may from time
to time make, amend, supplement or repeal the Bylaws; provided, however, that the stockholders may change or repeal any Bylaw adopted by the Board of Directors by the affirmative vote of the holders of a majority of

 
the voting power of all of the then outstanding shares of the capital stock of the Corporation; and, provided further, that no amendment or supplement to the Bylaws adopted by the Board of
Directors shall vary or conflict with any amendment or supplement thus adopted by the stockholders. 
 ARTICLE VI 

The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide. 

ARTICLE VII 
 To the fullest extent permitted by
the Delaware General Corporation Law, as the same exists or as may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a
director. 
 The Corporation shall indemnify to the fullest extent permitted by law, any person made or threatened to be made a party to an action or
proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director, officer or employee of the Corporation or any predecessor of the Corporation, or serves or served at
any other enterprise as a director, officer or employee at the request of the Corporation or any predecessor to the Corporation. 
 Neither any amendment or
repeal of this Article VII, nor the adoption of any provision of this Corporation’s Certificate of Incorporation inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII in respect of any
matter occurring, or any action or proceeding arising, or that, but for this Article VII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision. 

ARTICLE VIII 
 The Corporation is to have
perpetual existence. 
 ARTICLE IX 
 The number
of directors which shall constitute the whole Board of Directors shall be fixed by the Board of Directors in the manner provided in the Bylaws. 

ARTICLE X 
 Meetings of stockholders may be held
within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation may be kept (subject to any statutory provisions) outside the State of Delaware at such place or places as may be designated from time to time by the
Board of Directors in the Bylaws of the Corporation.EX-4.3

 Exhibit 4.3 

STOCK PURCHASE AGREEMENT 
 This
Stock Purchase Agreement (the “Agreement”) is made as of October 23, 2013 (the “Effective Date”), by and between Cytori Therapeutics, Inc., a Delaware corporation (the “Company”), and Lorem Vascular,
Pty. Ltd., an Australia corporation located at Level 12, 2 Queen Street, Melbourne 3000, Australia (“Purchaser”). 
 1.
Sale of Common Stock (the “Private Placement”). Subject to the terms and conditions of this Agreement, the Company will issue and sell to Purchaser, and Purchaser agrees to purchase from the Company: 

(a) Four Million unregistered shares of the Company’s common stock (the “Initial Shares”) at a price of Three Dollars (US$3.00)
per share for a total purchase price of Twelve Million US Dollars (US$12,000,000) (the “Initial Purchase Price”) at the 1st Closing (as defined below); and 

(b) Four Million unregistered shares of the Company’s common stock (the “Secondary Shares”) at a price of Three Dollars
(US$3.00) per share for a total purchase price of Twelve Million US Dollars (US$12,000,000) (the “Secondary Purchase Price”) at the 2nd Closing (as defined below). 

2. Purchase. The purchase and sale of the Initial Shares and the Secondary Shares under Section 1 of this Agreement shall
occur at the principal office of the Company as follows: 
 (a) Within three (3) calendar days of the execution of this Agreement by
the parties (the “1st Closing”). At the 1st Closing, Purchaser shall deliver the Initial Purchase Price to Company by wire transfer,
or by alternate means agreed between the Parties, and the Company shall deliver a certificate representing the Initial Shares to Purchaser. 

(b) Within sixty (60) calendar days after the Effective Date (the “2nd
Closing”). At the 2nd Closing, Purchaser shall deliver the Secondary Purchase Price to the Company by wire transfer, or by alternate means agreed between the Parties, and the Company shall
deliver a certificate representing the Secondary Shares to Purchaser. 
 (c) For purposes of reference for the remainder of this Agreement:
(i) the Initial Shares and the Secondary Shares shall be referred to collectively as the “Shares”, and (ii) the Initial Purchase Price and the Secondary Purchase Price shall collectively be referred to as the “Purchase
Price”. 
 3. Limitations on Transfer of Shares. Purchaser shall not assign, encumber or dispose of any interest in the
Shares except in compliance with applicable securities laws and regulations of applicable countries and stock exchanges. It is Purchaser’s responsibility to familiarize itself with such laws and regulations. 

4 Company’s Representation. The Company hereby represents and warrants to the Purchaser as follows as of the Effective Date
of this Agreement: 
 (a) The Company is duly organized and validly existing under the laws of the State of Delaware and has all requisite
corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. 

 (b) The Company has the right and power to enter into and perform its obligations under this
Agreement; has taken or will take prior to Closing all necessary corporate actions required to enter into and perform its obligations under this Agreement; and this Agreement constitutes the legal, valid and binding obligation of the Company,
enforceable in accordance with its terms. 
 (c) The execution of this Agreement and the consummation of the transactions contemplated
hereby will not result in a breach of any of the terms or provisions of, or constitute a default under, any agreement, or other instrument to which the Company is a party or by which it is bound. 

(d) All consents, approvals, authorizations and other requirements prescribed by any law, rule or regulation which must be obtained or
satisfied by the Company in order to permit the consummation of the transactions contemplated by this Agreement have been or will be obtained and satisfied prior to Closing. 

(e) The authorized capital of the Company consists solely of 145,000,000 authorized shares of common stock, and 5,000,000 shares of preferred
stock. 
 (f) The Shares, when issued, sold and delivered in accordance with the terms of this Agreement for the Purchase Price, will be
duly and validly issued, fully paid and non-assessable and will be delivered to the Purchaser, free and clear of liens, encumbrances (other than securities law restrictions), equities or claims. 

(g) The Company’s latest audited financial statements as of and for the year ended December 31, 2012, and any up to date Information
(as defined below) provided to Purchaser in connection with this purchase, taken together, fairly represent the true financial position of the Company in all material respects and in conformity with generally accepted accounting principles applied
on a consistent basis for the periods represented. 
 5. Investment Representations. In connection with the purchase of the
Shares, Purchaser makes the following representations and warranties to the Company as of the Effective Date and as of the date of the Closing: 

(a) This Agreement has been duly authorized and executed by Purchaser and, when delivered by Purchaser in accordance with its terms, will
constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms. 
 (b) Purchaser
understands that Company is a reporting company under the U.S. Securities Exchange Act, and its various periodic reports and other SEC filings are available for public inspection on the EDGAR system at www.sec.gov. Purchaser further acknowledges
that Purchaser and Purchaser’s advisors have had the opportunity to ask questions of and receive answers from the Company’s management concerning this investment. Purchaser is aware of the Company’s business affairs and financial
condition based on the said public available information and the answers from the Company’s management (the “Information”) and Purchaser and Purchaser’s advisors has evaluated the merits and risks of an investment in the Company
and decided to acquire the Shares based on such Information. 
 (c) Purchaser understands that the Shares have not been registered under the
U.S. Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser’s investment intent as expressed herein. 

  
 -2- 

 (d) Purchaser understands that the Shares are “restricted securities” within the
meaning of applicable U.S. federal and state securities laws and that, pursuant to these laws, Purchaser must hold the Shares indefinitely unless they are registered under the U.S. Securities and Exchange Commission and qualified by state
authorities and resold pursuant to the requirements of such registration/qualification, or an exemption from such registration and qualification requirements is available (e.g., Rule 144 or Regulation S). Purchaser further acknowledges that if an
exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and requirements relating to the Company which
are outside of Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. 
 (e) Purchaser is an
“accredited investor,” as defined in US Securities Act Rule 501. 
 (f) Purchaser has not entered into any agreement to pay
commissions to any persons with respect to the purchase or sale of the Shares, except commissions for which Purchaser will be responsible. 

(g) Purchaser understands and acknowledges that no Australian or United States federal or state agency, governmental authority, regulatory
body, stock exchange or other entity has made any finding or determination as to the merits of this investment, nor have any such agencies, governmental authorities, regulatory bodies, stock exchanges or other entities made any recommendation or
endorsement with respect to the Shares. 
 (h) Purchaser, in evaluating the merits of an investment in the Shares, is not relying on the
Company, its counsel, or any financial or other advisor to the Company for an evaluation of the tax, legal or other consequences of an investment in the Shares. 

(i) Purchaser is purchasing the Shares for investment for its own account only and not with a view to, or for resale in connection with, any
“distribution” thereof within the meaning of the U.S. Securities Act. 
 6. Legends. The certificates overlying the
Shares shall bear the following legends: 
 “The shares of common stock of Cytori Therapeutics, Inc. represented hereby have not been
registered under the United States Securities Act of 1933, as amended (the “Securities Act”). These securities may not be offered, sold, pledged or otherwise transferred (nor may exposure with respect to the shares otherwise be hedged)
except (A)(1) pursuant to an effective registration statement under the Securities Act, (2) pursuant to an exemption from registration under the Securities Act provided by Rule 144 thereunder (if available), or (3) pursuant to another
valid exemption from registration under the Securities Act (if available), and (B) in each case in accordance with all applicable securities laws of the States of the United States. No representation can be made as to the availability of the
exemption provided by Rule 144 under the Securities Act for re-sale of the shares.” 
 7. Registration. The Company shall
within 5 business days after receipt of funding from each of the 1st Closing and the 2nd Closing, use reasonable efforts to, promptly prepare
and file with the US Securities and Exchange Commission (the “Commission”) a Registration Statement covering the resale of the Shares for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement
shall be on Form S-3 (except if the Company is not then eligible to register for resale the Shares on Form S-3, in which case such registration shall be on another appropriate form in accordance with the US Securities Act and the rules promulgated
thereunder). The Company shall use its reasonable efforts to cause the Registration Statement to be declared effective under the US Securities Act 

  
 -3- 

 
within 45 business days after such filing. The Company shall keep such Registration Statement continuously effective under the Securities Act for a period of two years, or until the date upon
which all of the Shares may be sold pursuant to Rule 144 under the Securities Act, whichever occurs first (the “Effectiveness Period”). 

8. Registration Procedures; Company’s Obligations. In connection with the obligation for the registration of the Shares
above, the Company shall: 
 (a) Furnish to the Purchaser a copy of the Registration Statement as proposed to be filed. 

(b) Prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement as may be
necessary to keep the Registration Statement continuously effective as to the applicable Shares for the Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so
supplemented or amended to be filed pursuant to Rule 424 (or any similar provisions then in force) promulgated under the Securities Act; and (iii) respond promptly to any comments received from the Commission with respect to the Registration
Statement or any amendment thereto and promptly provide the Purchaser true and complete copies of all correspondence from and to the Commission relating to the Registration Statement. 

(c) Notify the Purchaser (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to the Registration Statement is
proposed to be filed, (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with
respect to the Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any request by the Commission or any other Federal or state governmental authority for amendments or supplements to the
Registration Statement or Prospectus or for additional information; (iii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement covering any or all of the Shares or the initiation of any
proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Shares for sale in any state of the U.S., or the initiation
or threatening of any proceeding for such purpose. 
 (d) Use its reasonable commercial efforts to avoid the issuance of, or, if issued,
obtain the withdrawal of, (i) any order suspending the effectiveness of the Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Shares for sale in any state of the U.S., at
the earliest practicable moment. 
 (e) If requested by the Purchaser, (i) promptly incorporate in a Prospectus supplement or
post-effective amendment to the Registration Statement such information as the Company reasonably agrees should be included therein, and (ii) make all required filings of such Prospectus supplement or such post-effective amendment as soon as
practicable after the Company has received notification of the matters to be incorporated in such Prospectus supplement or post-effective amendment. 

(f) Promptly furnish to Purchaser, without charge, one copy of the Registration Statement and any amendment thereto, and such number of copies
of the Prospectus and all amendments and supplements thereto and such other documents as Purchaser may reasonably request in order to facilitate its disposition of Shares. 

  
 -4- 

 (g) Use its reasonable commercial efforts to register or qualify or cooperate with the selling
Purchaser in connection with the registration or qualification (or exemption from such registration or qualification) of such Shares for offer and sale under the securities or Blue Sky laws of each state of the U.S. as the Purchaser reasonably
requests in writing, to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable the disposition in such states of the
Shares covered by a Registration Statement; provided, however, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or to take any action that would subject it
to general service of process in any such jurisdiction where it is not then so subject or subject the Company to any tax in any such jurisdiction where it is not then so subject. 

(h) Use its reasonable efforts to cause all Shares to be listed on any U.S. national securities exchange (such as the NASDAQ Global Market),
U.S. quotation system, or U.S. over-the-counter bulletin board, if any, on which the same securities issued by the Company are then listed. 

(i) Notwithstanding any other provision of this Section 8, the Company shall have the right at any time to require that the
Purchaser suspend open market offers and sales of its Common Stock pursuant to a Registration Statement whenever in the reasonable, good-faith judgment of the Company’s Board of Directors or a committee thereof, permitting open market offers
and sales of such securities would result in serious harm to the Company (the “Suspension Right”). The Company may use the Suspension Right and suspend the sale of Shares under the Registration Statement one time every three
months or three times in any twelve month period, provided that the Company may not suspend its obligation for more than 60 days in the aggregate in any 12 month period. 

9. Registration Procedures; Purchaser’s Obligations. In connection with the registration of the Shares, the Purchaser shall
(i) not sell any Shares under the Registration Statement until it has received copies of the Prospectus as then amended or supplemented as contemplated in Section 8(f) and the notice from the Company that such Registration Statement and
any post-effective amendments thereto have become effective as contemplated by Section 8, (ii) comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Shares pursuant to the
Registration Statement, and (iii) furnish to the Company information regarding such Purchaser and the distribution of such Shares as is required by law to be disclosed in the Registration Statement. 

10. Registration Expenses. 

All reasonable fees and expenses incident to the performance of or compliance with the obligations under Section 8 of this Agreement
shall be borne by the Company whether or not any Shares are sold pursuant to the Registration Statement. 
 11.
Indemnification. 
 (a) Indemnification by the Company. The Company shall indemnify and hold harmless Purchaser, its
permitted assignees, officers, directors, agents, brokers, investment advisors and employees, each person who controls Purchaser or a permitted assignee (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act) and the officers, directors, agents and employees of each such controlling person, and the respective successors, assigns, estate and personal representatives of each of the foregoing, to the fullest extent permitted by applicable law, from and
against any and all claims, losses, damages, liabilities, penalties, judgments, costs (including, without limitation, costs of investigation) and expenses (including, without limitation, reasonable attorneys’ fees and expenses) (collectively,
“Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of 

  
 -5- 

 
a material fact contained in the Registration Statement, any Prospectus, as supplemented or amended, if applicable, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except (i) to the extent, but
only to the extent, that such untrue statements or omissions are based solely upon information regarding the Purchaser furnished in writing to the Company by the Purchaser expressly for use therein, or (ii) as a result of the failure of the
Purchaser to deliver a Prospectus, as amended or supplemented, to a purchaser in connection with an offer or sale. The Company shall notify the Purchaser promptly of the institution, threat or assertion of any Proceeding of which the Company is
aware in connection with the transactions contemplated by this Agreement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of an Indemnified Party (as defined in Section 11(b) hereof) and
shall survive the transfer of the Shares by the Purchaser. 
 (b) Conduct of Indemnification Proceedings. If any Proceeding shall be
brought or asserted against any Person entitled to indemnity pursuant to Section 11(a) hereunder (an “Indemnified Party”), such Indemnified Party promptly shall notify the Person from whom indemnity is sought (the
“Indemnifying Party) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in
connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent
that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party. 

An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have failed
promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both
such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party
(in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof
and such counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld,
conditioned or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, which consent shall not unreasonably be withheld, conditioned or delayed, effect any settlement of any pending Proceeding in respect of
which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. 

All reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with
investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within 20 business days of written notice thereof to the Indemnifying Party (regardless of
whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the
extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder or pursuant to applicable law). 

  
 -6- 

 (c) The indemnity agreement contained in this Section is in addition to any liability that the
Indemnifying Parties may have to the Indemnified Parties. 
 12. Board Member Seat. Promptly after the closing of the Initial
Share Purchase, the Company’s Board of Directors shall elect a candidate, designated by Purchaser, to serve as a member of the Company’s Board of Directors. 

13. No Other Special Rights. Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company
to negotiate, or to decline to negotiate, any contractual relationship with Purchaser, nor the right or power of Purchaser to negotiate, or to decline to negotiate, any contractual relationship with the Company. 

14. Miscellaneous. 

(a) Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties
hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. 

(b) Entire Agreement; Enforcement of Rights. This Agreement sets forth the entire agreement and understanding of the parties
relating to the subject matter herein and merges all prior discussions between them with regard to such subject matter. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless
in writing signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party. 

(c) Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, such provision shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the
remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof. The parties will endeavor in good faith
negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). 

(d) Construction. This Agreement is the result of negotiations between and has been reviewed by both of the parties hereto and
their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of both of the parties hereto, and no ambiguity shall be construed in favor of or against either one of the parties hereto. 

(e) Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when
delivered personally or sent and confirmed by fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such party’s address or fax number as set
forth below or as subsequently modified by written notice. 
 (f) Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

  
 -7- 

 The parties have executed this Stock Purchase Agreement as of the Effective Date. 

 

	
	 COMPANY:
  

CYTORI THERAPEUTICS, INC.

	  
 By: /s/ Christopher J. Calhoun

	          Christopher J. Calhoun

  

			
	Title:	 	Chief Executive Officer
	
	 Address:
 3020 Callan Road

San Diego, CA 92121
  

	Fax:	 	US 858-458-0994

  

			
	Date:	 	October 29, 2013

  

	
	 PURCHASER:
  

LOREM VASCULAR PTY. LTD.

	  
 By: /s/ Kian Thiam Lim

	          Kian Thiam Lim
	  
 Title: Director

 
 Address:

Level 12, 2 Queen Street
 Melbourne 3000

Australia

  
 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]